Skip to content

Diana Athonvarangkul

NPI 1275980450ActiveIndividual· Internal Medicine, Endocrinology, Diabetes & Metabolism· New Haven, CT

Internal Medicine, Endocrinology, Diabetes & Metabolism in New Haven, Connecticut, licensed in CT, with an NPI issued in May 2016. Ultragenyx Pharmaceutical Inc. reported $11,000 in payments in 2025, mostly consulting fees.

Overview

NPI1275980450
StatusActive
Entity typeIndividual
Sole proprietorYes
NPI issuedMay 18, 2016
Last updated in NPPESJan 27, 2023
Certified by providerJan 27, 2023

Specialties and licenses

About license numbers in NPPES

Exclusion screening

ListResultDetails
HHS-OIG LEIE · Oct 9, 2026No matchChecked by NPI and by name + state
North Carolina Medicaid · Nov 10, 2026No match—
New York OMIG · Nov 10, 2026No match—
Ohio Medicaid · Nov 10, 2026No match—
Pennsylvania Medicheck · Nov 10, 2026No match—
Washington HCA · Nov 10, 2026No match—

Official OIG search · How matching works ·Bulk check a roster

Medicare

Enrollment (PECOS)Not in the public enrollment file of Oct 1, 2026

Medicare sources and data years

Industry payments (Open Payments)

  • 2025$11,000 · 1 payment from 1 company

Top paying companies in 2025

CompanyAmountPayments
Ultragenyx Pharmaceutical Inc.$11,0001

What the 2025 payments were for

  • Consulting Fee$11,000 · 1 payment

Receiving payments does not imply wrongdoing. What Open Payments covers ·original records

Other Internal Medicine, Endocrinology, Diabetes & Metabolism providers in New Haven

All Internal Medicine, Endocrinology, Diabetes & Metabolism providers in Connecticut →